ABBV-291

Phase 1Small molecule

AbbVie

ABBV-291 is one of 61 small molecule programs targeting Non-Hodgkins Lymphoma. It is currently in Phase 1.

Indications

Total Trials

Active Trials

Competitors

Pipeline

Status by Indication[3][1]

Indication

Non-Hodgkins LymphomaActive, not recruiting

Non-Hodgkins LymphomaPhase 1

Active, not recruiting

Competition

Competitive Landscape

67 competitors in Non-Hodgkins Lymphoma

#DrugCompanyPhaseTrials

Fludara

Sanofi

Approved

1 2

Aliqopa

Bayer

Approved

1 3

Calquence

AstraZeneca

Approved

1 4

Istodax

Gleevec

Ibrance

Afinitor

Gemzar

Trexall

Cytosar

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Timeline

Expected Milestones

Q2 2027

Phase 1Active, not recruiting

Non-Hodgkins Lymphoma

NCT06667687

Clinical

Trials by Indication[1]

Non-Hodgkins Lymphoma1 trial

A Phase 1 First-In-Human Study Evaluating Safety, Pharmacokinetics, and Efficacy of ABBV 291 in Non-Hodgkin's Lymphoma

Active, not recruiting· AbbVie logo

AbbVie·Phase 1·NCT06667687·21 enrolled

Sources

References

[1]
ClinicalTrials.gov — 1 trial record for ABBV-291. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — ABBV-291 compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for ABBV-291. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — AbbVie company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Small molecule[2]
Highest Phase: Phase 1[1]
Company: AbbVie

ABBV-291

Status by Indication[3][1]

Competitive Landscape

Expected Milestones

Q2 2027

Trials by Indication[1]

Non-Hodgkins Lymphoma1 trial

References

Drug Info

Quick Facts

Related News